Podcast 15 Aug 2025Are next-generation psychedelics the way forward for addressing treatment resistant depression? This week’s guest is Cosmo Feilding of Beckley PsyTech, a UK biotech working with next generation psychedelics that could redefine depression treatment. August 15, 2025 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
In Depth 27 Jun 2025 Psychedelics sans side effects: neuroplastogens gain ground The past year has seen several developments in the neuroplastogens field, including Elkedonia’s seed funding to address neuropsychiatric disorders. June 27, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 21 Mar 2025 Depression drug trials are failing—and placebos are to blame In this article, we examine recent clinical trial failures and discuss potential pathways forward for antidepressant drug research. March 21, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 29 Nov 2024 Trump’s healthcare picks: Who they are and what they mean for the biopharma industry Trump’s nominees for top healthcare roles have sparked significant debate. So, what do their appointments signal for the future of healthcare in the U.S.? November 29, 2024 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 13 May 2024 New antidepressants: tackling treatment resistant depression Take a look at how new antidepressants can more effectively tackle treatment resistant depression compared to more traditional treatments. May 13, 2024 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 13 Mar 2024 From LSD to healing minds: Where are we standing in psychedelic drug development? Delve into the growing sector of psychedelic drug development to find out where we are coming from, and where we are standing in the field. March 13, 2024 - 13 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 17 Aug 2023 Six Toronto-based biotech companies to watch this year The capital city of the Canadian province of Ontario, Toronto, is home to the Discovery District, a commercial hub that sees biotech and healthcare innovations and companies at its prime. Having witnessed the largest growth in tech jobs in North America between 2015 and 2020, Toronto, like Vancouver, is a significant contributor towards Canada’s life […] August 17, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 23 Feb 2023 Depression trial gets green light Beckley Psytech Ltd has received investigational new drug (IND) approval from the U.S. Food and Drug Administration (FDA) for a global multi-site phase IIb study exploring the safety, efficacy and tolerability of two doses of its lead compound, BPL–003, in patients with treatment resistant depression (TRD). BPL-003 is the Beckley Psytech’s novel synthetic formulation of […] February 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 Potential new lead compounds for treatment of depression and anxiety disorders Currently, various classes of drugs are available for the treatment of mental illnesses – such as depression and anxiety disorders. However, although these drugs have benefits, they can also be associated with adverse side-effects. A research group has conducted a study to identify new drugs that could potentially be used for the treatment of neuropsychiatric […] November 15, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 Beckley Psytech completes treatment resistant depression and alcohol use disorder study Beckley Psytech, a private, clinical-stage biotechnology company dedicated to addressing neuropsychiatric conditions through the novel application of psychedelic medicines, has completed its phase I clinical study of BPL-003, a synthetic intranasal formulation of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT), which is under development for treatment resistant depression and alcohol use disorder. The double-blind, randomized, single ascending dose study […] November 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2022 Beckley Psytech acquires Eleusis Therapeutics Beckley Psytech Limited has entered into a definitive agreement to acquire clinical-stage life science company Eleusis Therapeutics Limited in an all equity transaction. Under the terms of the agreement, which has been approved by shareholders, Beckley Psytech has acquired 100% of Eleusis, receiving full developmental and commercial rights for the company’s assets, which will further […] October 24, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Aug 2022 Axsome Therapeutics’ MDD treatment gets green light from FDA The U.S. Food and Drug Administration (FDA) has approved Axsome Therapeutics, Inc.’s Auvelity tablets for the treatment of major depressive disorder (MDD) in adults. Auvelity (dextromethorphan HBr -bupropion HCl) is the first and only rapid-acting oral medicine approved for the treatment of MDD with labeling of statistically significant antidepressant efficacy compared to placebo starting at […] August 19, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email